Tripod-Fix Vertebral Body Augmentation System in Osteoporotic Vertebral Compression Fractures Treatment
NCT ID: NCT06261242
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
12 participants
INTERVENTIONAL
2023-06-16
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Short Segment Mono-axial and Poly-axial Pedicle Screw Fixation for Thoracolumbar Fractures
NCT04032054
A Retrospective Comparison Between CPS and HC Techniques for Osteoporotic Fractures in the Thoracic or Lumbar Spine
NCT05130242
Posterior Percutaneous Pedicle Screw Fixation for Acute Thoracolumbar Vertebral Fractures
NCT02963571
Short Segment Fixation in Thoracolumbar Osteoporotic Fracture
NCT02719340
Assessment of the Feasibility of Using a Preoperative Surgical Fracture Analysis Tool
NCT07193524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stated willingness to comply with all study procedures and availability for the duration of the study.
3. Male or female with at least 50 years of age.
4. 1 painful VCF which meet all of the following criteria:
1. Fracture due to diagnosed or presumed underlying osteoporosis (T-score \< -2.5 points).
2. VCF between T7 and L4.
3. Fracture age \< 3 months.
4. VCF shows loss of height in the anterior, mid or posterior third of the vertebral body from an estimated pre-fracture configuration of at least 15% but not more than 40% based on X-ray, CT or MRI at baseline.
5. The Index fracture is acute or persistent (not healed), as demonstrated by MRI or bone scan.
5. Patient has failed conservative medical therapy, complementary and alternative medicine, defined as either having a VAS back pain score of ≥ 50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥ 70 mm at 2 weeks after initiation of fracture care. If patients with pain ≥ 70 mm at baseline continued to deteriorate as demonstrated by increasing VAS score and/or progressive vertebral collapse, treatment might be initiated after 1 week of conservative care.
6. Investigator believes target vertebral body is suitable for Tripod-Fix procedure (e.g., appropriate pedicle diameter) assessed on radiography preoperative.
7. Patient has an ODI score of ≥ 30/100.
Exclusion Criteria
2. Target VCF is diagnosed as an osteonecrosis.
3. Segmental kyphosis of target vertebral compression \> 30°.
4. Any prior surgical treatment for a VCF or other surgical procedure on the target vertebral body or adjacent level.
5. The patient has uncontrolled systemic diabetes (A1c \> 10) and /or uncontrolled hypertension (patient requiring 3 or more anti-hypertensive drugs).
6. Pre-existing or clinically unstable neurologic deficit.
7. Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated.
8. Any physical exam evidence of myelopathy, radiculopathy, or coagulopathy.
9. Disabling back pain due to causes other than acute fracture, or any other condition that requires daily narcotic medication, such as clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis).
10. Patient not able to walk without assistance prior to fracture.
11. Any radiographic evidence of cortical disruption, burst fractures and pedicle fracture.
12. Translation \> 4 mm or Spondylolisthesis \> Grade 1 at target vertebral body.
13. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.).
14. In the investigator's opinion, a patient with any other medical illness or condition which may not be suitable to participate in the study, including but not limited to: A medical contraindication to spinal surgery and/or general anesthesia, such as Patients on chronic anti-coagulation. (Patients stop the treatment 8 days before surgery with a threshold for normal being INR \< 1.1 and platelets \> 100,000 are not limited to this.)
15. Prior history of intolerance or allergic reaction to titanium and/or one of the components of the PMMA cement.
16. Active systemic or local infection at baseline.
17. Body mass index \> 40.
18. Patients affected by severe cardiopulmonary deficiencies.
19. In the investigator's opinion, a patient with any other medical illness or condition which may not be suitable to participate in the study, including but not limited to: Likely to impair long-term follow-up (e.g., cancer).
20. Any evidence of alcohol or drug abuse.
21. Uncontrolled psychiatric disorders are defined by the DSM V or severe dementia.
22. Currently on anti-cancer therapy or anti-HIV therapy.
23. Life expectancy is less than the study duration or undergoing palliative care.
24. Participating in any other investigational study.
25. On long-term steroid therapy (steroid dose ≥ 30 mg /day for \> 3 months).
26. Known to be involved in spinal litigation.
27. Pregnant women as confirmed by positive pregnancy test or considering getting pregnant during study participation.
28. Presenting loss of vertebral height \> 50% compared to estimated pre-fracture height.
29. Interspinous-process widening.
30. Sclerotic fracture or pseudarthrosis.
31. Patient is a prisoner or not in the wards of the court.
32. Patients with contraindications to MRI and bone scan.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cheng-Kung University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheng-Li Lin
Director of Spinal Division/Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheng-Li Lin
Role: PRINCIPAL_INVESTIGATOR
NCKUH Department of Orthopedics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cheng Kung University Hospital Department of Orthopedics
Tainan City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TWM-C-2201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.